Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals

AIDS Research and Human Retroviruses

Volumn 19, Issue 9, 2003, Pages 785-792

  Cavacini, Lisa A ^a,b   Kuhrt, David ^a   Duval, Mark ^a   Mayer, Kenneth ^c   Posner, Marshall R ^a,b,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Fenway Community Health   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; POLYCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LABORATORY TEST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; NEUTRALIZATION TESTS;

EID: 0141481967     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203769232584     Document Type: Article

References (65)

1. Burton D and Montefiori D: The antibody response in HIV-1 infection. AIDS 1997;11:S87-S98.
2. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-216.
3. Cao Y, Limo Q, Zhang L, Safrit J, and Ho D: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
4. Cavacini L, Emes C, Power J, et al.: Serum antibodies reactive to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody are associated with prognosis. J Acquir Immune Defic Syndr 1993;10:1093-1107.
5. Stamatatos L and Cheng-Mayer C: An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998;72:7840-7845.
6. Stamatatos N, Mascola J, Kalyanaraman V, et al.: Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monmeric gp120 and oligomeric gp140. J Virol 1998;72:9656-9667.
7. Moore J and Ho D: Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-875.
8. Kang C-Y, Hariharan K, Posner M, and Nara P: Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J Immunol 1993;151:449-457.
9. Spenlehauer C, Saragosti S, Fleury H, et al.: Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol 1998;72:9855-9864.
10. Moore JP, Cao Y, Ho DD, and Koup RA: Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-5155.
11. Khouri J, McIntosh K, Cavacini L, et al.: Vertical transmission of HIV-1: Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest 1995;95:732-737.
12. Trkola A, Purtscher M, Muster T, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
13. Purtscher M, Trkola A, Gruber G, et al.: A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:1651-1658.
14. Cavacini L, Peterson J, Nappi E, et al.: Minimal incidence of serum antibodies reactive with intact primary isolate virions in HIV-1 infected individuals. J Virol 1999;73:9638-9641.
15. Moog C, Fleury H, Pellegrin I, Kim A, and Aubertin A: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-3741.
16. Pilgrim A, Pantaleo G, Cohen O, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:924-932.
17. Lewis J, Balfe P, Arnold C, et al.: Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol 1998;72:8943-8951.
18. Albert J, Abrahamsson B, Nagy K, et al.: Rapid development of isolate specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
19. Lathey J, Pratt R, and Spector S: Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997;175:231-232.
20. Nyambi P, Miroslaw G, Bastini L, et al.: Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998;72:9384-9391.
21. Nyambi P, Mbah H, Burda S, et al.: Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000;74:7096-7107.
22. Wyatt R, Kwong P, Desjardins E, et al.: The antigenic structure of HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
23. Wyatt R, Moore J, Accola M, et al.: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
24. Wyatt R, Desjardin E, Oleshevsky U, et al.: Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol 1997;71:9722-9731.
25. Bou-Habib D, Roderiquez G, Oravecz T, et al.: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
26. Thali M, Furman C, Wahren B, et al.: Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr 1992;5:591-599.
27. Normansell DE: Human immunoglobulin subclasses. Diagn Clin Immunol 1987;5:115-128.
28. Schur PH: IgG subclasses - a review. Ann Allergy 1987;58:89-96.
29. Cooper I, Robertson D, Granzow R, and Greenspan N: Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 1994;31:577-584.
30. Cooper L, Shikhman A, Glass D, et al.: Role of heavy chain constant domains in antibody-antigen interaction: Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J Immunol 1993;150:2231-2242.
31. Schneider WP, Wensel TG, Stryer L, and Oi VT: Genetically engineered immunoglobulins reveal structural features controlling segmental flexibility. Proc Natl Acad Sci USA 1988;85:2509-2513.
32. Horgan C, Brown K, and Pincus SH: Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J Immunol 1993;150:5400.
33. Scharf O GH, King LR, Eller N, Frazier D, Golding B, and Scott DE: Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol 2001;75:6558-6565.
34. Roux K, Strelets L, and Michaelsen T: Flexibility of human IgG subclasses. J Immunol 1997;159:3372-3382.
35. Roux K, Strelets L, Brekke O, Sandlie I, and Michaelsen T: Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: A role for flexibility and geometry. J Immunol 1998;161:4083-4090.
36. Ishizaka S, Piacente P, Silva J, and Mishkin E: IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 1995;172:1108-1111.
37. Cooper L, Schimenti L, Glass D, and Greenspan N: H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J Immunol 1991;146:2659-2663.
38. Pincus S, Messer K, Schwzartz D, et al.: Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccines. J Clin Invest 1993;91:1987-1996.
39. Bomford R, Stapleton M, Winsor S, McKnight A, and Andronova T: The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retroviruses 1992;8:1765-1771.
40. Kovacsovics-Bankowski M, Carini C, Kashala O, and Essex M: Isotypic distribution of HIV-1 specific antibodies in individuals from central Africa. Viral Immunol 1992;5:243-248.
41. Khalife J, Guy B, Capron M, et al.: Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses 1988;4:3-9.
42. McDougal J, Kennedy M, Nicholson J, et al.: Antibody response to human immunodeficiency virus in homosexual men: relation of antibody specificity, titer and isotype to clinical status, severity of immunodeficiency, and disease progression. J Clin Invest 1987;80:316-324.
43. Klasse P, Blomberg J, and Pipkorn R: Differential IgG subclass responses to epitopes in transmembrane protein of HIV-1. Viral Immunol 1990;3:89-98.
44. Lal R, Heiba I, Dhawan R, Smith E, and Perine P: IgG subclass responses to human immunodeficiency virus-1 antigens: Lack of IgG2 responses to gp41 correlates with clinical manifestations of disease. Clin Immunol Immunopathol 1991;58:267-277.
45. Cavacini L, Emes C, Powers J, and Posner M: Effect of antibody valency and size on interaction with cell surface expressed virions and virus neutralization. J Immunol 1994;52:2538-2545.
46. Cavacini L, Emes C, Power J, et al.: Influence of heavy chain constant region on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J Immunol 1995;155:3638-3644.
47. Cavacini L, Samore M, Gambertoglio J, et al.: Phase I study of a human monoclonal antibody against the CD4 binding site of HIV-1/gp120. AIDS Res Hum Retroviruses 1998;14:545-550.
48. Cavacini L, Emes C, Power J, et al.: Human monoclonal antibodies to the V3 loop of gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993;6:353-358.
49. Tan LK, Shopes RJ, Oi VT, and Morrison SL: Influence of the hinge region on complement activation, Clq binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci USA 1990;87:162-166.
50. Dangl JL, Wensel TG, Morrison SL, et al.: Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988;7:1989-1994.
51. Sandlie I and Michaelsen T: Engineering monoclonal antibodies to determine the structural requirements for complement activation and complement mediated lysis. Mol Immunol 1991;28:1361-1368.
52. Brekke OH, Michaelsen T, Sandin R, and Sandlie I: Activation of complement by an IgG molecule without a genetic hinge. Nature 1993;363:628-630.
53. Forthal DN, Landucci G, and Daar ES: Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001;75:6953-6961.
54. Linde A, Sundqvist VA, Mathiesen T, and Wahren B: IgG subclasses to subviral components. Monogr Allergy 1988;23;27.
55. Raux M, Finkielsztejn L, Salmon-Ceron D, et al.: IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2000;16:583-594.
56. Klasse PJ, Berntorp E, and Hansson BG: An aberrant subclass pattern of HIV-specific immunoglobulin G in sera from haemophiliacs. AIDS 1988;2:311-313.
57. Ngo-Giang-Huong N, Candotti D, Goubar A, et al.: HIV type 1-specific IgG2 antibodies: Markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001;17:1435-1446.
58. Wang Z-H, Kjellberg L, Abdalla H, et al.: Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000;181:456-462.
59. Lal RB, Buckner C, Khabbaz RF, et al.: Isotypic and IgG subclass restriction of the humoral immune responses to human T-lymphotropic virus type-I. Clin Immunol Immunopathol 1993;67:40-49.
60. Isa MB, Maartinez L, Giordano M, et al.: Measles virus specific immunoglobulin G isotype immune response in early and late infections. J Clin Microbiol 2001;39:170-174.
61. Gregorek H, Madalinski K, Woynarowski M, et al.: The IgG subclass profile of anti-HBs response in vaccinated children and children seroconverted after natural infection. Vaccine 2000;18:1210-1217.
62. Coffman RL, Lebman DA, and Rothman P: Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993;54:229-270.
63. +) B cells to secrete IgG1 and IgG3. J Exp Med 1994;179:757-762.
64. Kawano Y, Noma T, and Yata J: Regulation of human IgG subclass production by cytokines. J Immunol 1994;153:4948-4958.
65. Snapper CM and Mond JJ: Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993;14:15-17.